Introduction
The frequency of radical prostatectomy as treatment for patients with clinically localized prostate cancer varies over the world, from almost none performed in Denmark, 1 to a widespread use with many tens of thousands performed yearly in the United States during the late 1980s and 1990s. 2 The use of radical surgery as well as external radiation therapy is by and large based upon compilations of outcome in non-randomized patient series. Ongoing randomized treatment trials will give information regarding the ef®cacy of radical surgery 5 ± 10 y from now.
Available data suggest that the difference between local aggressive and deferred treatment is reasonably small up to 10 years after diagnosis. 3 ± 5 Many patients who die during this interval probably already had micrometastasis at diagnosis, but some may have had tumours that were curable. The bene®t of aggressive treatment in the patients with clinically localized prostate cancer and a short expected survival has consequently been questioned. 6 Also, in the series on deferred treatment there seem to be a proportion of patients with tumours that behave benignly, 7,8 but we do not know how large this proportion is. The course beyond 10 y of follow-up is a subject of debate. Patients managed noncuratively who die of prostate cancer after this point may be those without micrometastases and curable at diagnosis.
In the present study we describe the long-term prostate cancer mortality in patients with clinically localized prostate cancer managed noncuratively in a large populationbased setting. Our data add information for understanding the extent of possible over-treatment in a situation where all patients are treated with local aggressive therapy or, vice versa, the impact of under-treatment if all patients were managed noncuratively.
Material and methods
We identi®ed all men aged 45 ± 84 y with a recorded diagnosis of prostate cancer from 1 January, 1965, to 31 December, 1993, in the Finnish Cancer Registry. Patients in whom prostate cancer was diagnosed at autopsy or in death certi®cates only were excluded. In this patient population the absolute majority was managed with initial or deferred endocrine treatment. Few patients, if any, were given local therapy with curative intent, such as radical prostatectomy or radiation therapy, during the 1960s, 1970s and the early 1980s. The Finnish Cancer Registry is population-based and covers the whole country, with today approximately 5 million inhabitants. The law for both clinicians and pathologists mandates registration of patients with newly diagnosed tumours in this registry. The registry has been described in detail in a quality control study comprising the registrations entered from 1985 to 1988, in which 98% of all new cases of prostate cancer were registered. 9 The Cancer registry includes the date of diagnosis of cancer, method of diagnosis, tumour stage and, if appropriate, date and cause of death. It is linked annually to the ®les of deaths and emigration at the Central Statistical Of®ce in Finland. Cause of death is based on death certi®cates. Information on tumour stage is based on the reports from the treating physicians. The stage of prostate cancer is classi®ed in three categories;`localized' with no evident spread outside the prostate gland;`advanced' with evident local spread or with metastasis; and`unknown', if information on stage is lacking. A physician scrutinizes the information for inconsistencies before it is entered into the database.
The observation period started on 1 January, 1965 and ended on 31 December, 1994. The annual risk of dying of prostate cancer was calculated as the number of deaths from prostate cancer divided by the number of patients at risk. Disease-speci®c and overall survival were calculated using a life-table technique 10 and survival rates are given as means AE 2 standard errors (s.e.).
Results
During the study period, 26,055 men with prostate cancer who were alive at the time of diagnosis were registered. Their mean age was 72 y. In 759 patients the date but not the cause of death was recorded, leaving 25,296 patients for the analysis of disease-speci®c survival. Of these patients, 11,500 had localized tumours at the time of the diagnosis, 7599 had advanced tumours and the tumour stage was unknown in the remaining 6197. Of the patients with localized disease, 2252 were diagnosed from 1965 to 1974, 4011 from 1975 to 1984 and 5237 from 1985 to 1993. The mean age of the patients with localized disease at diagnosis was 72 y and 646 were between 45 and 59, 6603 were between 60 and 74, and 4251 patients were between 75 and 84 y of age. In the group with localized disease the diagnosis was based on investigation of histological specimens in 91.5% of the patients, on investigation of cytological specimens in 7.4% and in the remaining 1.1% on clinical investigation only.
Altogether 20,509 patients died during the follow-up and 12,409 (59%) died of prostate cancer. Of the 11,500 men with localized tumours, 7830 patients (68%) died during the observation period and of these 3526 (45%) died of prostate cancer (Table 1) . Of the 6907 patients with localized disease who died before 10 y observation, 3207 (46%) died of prostate cancer and of the 923 who died later than 10 y after the diagnosis, 319 (35%) died of prostate cancer (Table 1) . Of the 2252 patients with localized disease diagnosed from 1965 to 1974, ie those who could be followed up for 20 y or more, 1142 died of prostate cancer, 1022 died of intercurrent disease and 88 were alive at the end of the observation period. Of the patients diagnosed from 1965 to 1974 who died of prostate cancer, 122 died in the period from the beginning of year 11 to the end of year 20. Thus, 5% (122/2252) of the patients who could be followed for 20 y or longer died of Speci®c mortality from prostate cancer J Adolfsson et al prostate cancer in the interval between 11 and 20 y after diagnosis (cumulative incidence). The disease-speci®c survival rate in the group with localized tumours decreased up to about 23 y after the diagnosis and reached a plateau at approximately 30% thereafter (Table 2, Figure 1 ).
The yearly cumulative proportion of the patients with localized disease who died that died of prostate cancer increased during the ®rst 4 y of follow-up and then decreased with longer follow-up ( Figure 2 ). In each consecutive 5 y interval, the cumulative proportion of the patients with localized disease who died that died of prostate cancer decreased during follow-up (Table 3) . This pattern was seen for all times of diagnosis ( Table 3) .
The yearly risk of dying of prostate cancer for the patients with localized disease reached a maximum of approximately 7% 4 y after the diagnosis, whereupon it decreased during further follow-up (Figure 3) . The overall cumulative proportion of patients who died that died of prostate cancer was constant over follow-up time ( Table 4) .
The disease-speci®c survival rate was the lowest in the group diagnosed from 1965 to 1974 and increased the later the patients were diagnosed (Table 4, Figure 4 ). The disease-speci®c survival rate did not differ with age category (data not shown). Figure 2 The distribution over time of the yearly proportion of the patients who died that died of prostate cancer in the group diagnosed with localized prostate cancer (n 11,500) The ®gure is estimated from a model based on logistic regression. Figure 3 The yearly risk of dying of prostate cancer. Calculated as the number of deaths from prostate cancer divided by the number of patients at risk in the group diagnosed with localised prostate cancer (n 11,500). Speci®c mortality from prostate cancer J Adolfsson et al
The overall survival rates at 10 and 15 y follow-up were respectively 17% (2 s.e. AE 0.5%) and 7% (2 s.e. AE 0.5%) for all patients, 24% (2 s.e. AE 1.0%) and 11% (2 s.e. AE 0.8%) for patients with localized disease, and 4% (2 s.e. AE 0.5%) and 1% (2 s.e. AE 0.4%) for patients with advanced disease.
Discussion
In a population-based setting with a long-term follow-up of patients with apparently localized prostate cancer we found that with noncurative management nearly onethird of the patients with localized disease at diagnosis had tumours which were not lethal during three decades of follow-up. Early aggressive therapy does not seem to be needed for survival in this group. Also, nearly half of the patients who died did so of intercurrent diseases, irrespective of the length of the follow-up. After considering different sources of bias, especially misclassi®cation of metastatic disease at diagnosis, we conclude that the true ®gure may be higher (see below). Early aggressive treatment would not be bene®cial, in terms of survival, to patients dying of intercurrent diseases.
The often protracted course of localized prostate cancer brings the treatment decision down to a choice between unwanted morbidity from treatment, such as waning sexual function, voiding problems and bowel disorders, 11, 12 and possible bene®cial effects in terms of less late morbidity and prolonged survival. The present study adds information on the possible effects on survival by early aggressive therapy.
The great majority of the patients died before 10 y follow-up. Among those who died of prostate cancer before 10 y follow-up there may have been patients with initially curable tumours, but we cannot assess how large this proportion is. The cumulative incidence of death from prostate cancer during years 11 ± 20 of follow-up was 5% of all patients that could be followed for 20 y or more and with localized disease in the present series. Presumably, a large proportion of these patients were potentially curable by local aggressive treatment at diagnosis and a challenge is to learn how to identify these patients, as well as those who may have died before 10 y of follow-up with initially curable tumours, at the time of diagnosis. The generalizability of our data to today's patients is open to discussion (see below).
It can be argued that the precision of the present data regarding the metastatic status is low. The diagnostic intensity and the sensitivity of detecting bone metastasis have most certainly increased during the inclusion period. Probably some patients with unknown metastatic disease have been recorded in the register as having localized tumours, especially in the patients included early in the cohort. The median survival is approximately 3 y for patients with metastatic disease 13, 14 and an admixture of such patients to the group with localized disease may have resulted in false high prostate cancer mortality up to 5 ± 6 y after diagnosis. If the patients in our analysis with true metastatic disease could have been removed from the group with localized disease, the numerator indicating the total number of deaths from prostate cancer and the denominator indicating the total population would be smaller, but the latter would diminish proportionally less than the former. This means that the death rate from prostate cancer would have been lower, and consequently the rate of intercurrent death higher. Also, since the denominator decreases, and the numerator for events of prostate cancer death between 11 and 20 y of follow-up presumably is by and large unchanged, this bias implies that the true ®gure for the proportion of patients dying of prostate cancer during follow-up from 11 to 20 y is higher than that observed. The magnitude of this bias depends on how large the group with true, but undetected, metastatic disease is.
We cannot assess an ascertainment bias with respect to the causes of death in the Finnish Cancer Registry. There are no such data available regarding prostate cancer from this registry. However, in the Swedish Cancer Registry approximately 5% under-reporting of death of breast cancer was found. 15 If this also is true for prostate cancer in the Finnish Cancer Registry the 30% long-term disease-speci®c survival found in our study rightfully should be 5% lower. However, Gro È nberg et al 16 found in a population-based series of patients with prostate cancer in northern Sweden an almost exact correspondence between relative survival derived from the cancer registry and disease-speci®c survival derived from patients' ®les. These data suggest that the Scandinavian registries are accurate with respect to cause of death and that the ascertainment bias is probably small.
The disease-speci®c survival rate in the 11,500 patients with localized prostate cancer seemed to reach a plateau at approximately 30% 23 y after diagnosis. The plateau re¯ects a proportion of patients whose tumours are not lethal when managed noncuratively, ie without early local aggressive treatment. Immediate or delayed endocrine treatment was the standard management in Finland during the inclusion period. Therapies with curative intent such as radical prostatectomy and, to a lesser Speci®c mortality from prostate cancer J Adolfsson et al degree, irradiation were used increasingly during the last decade of the inclusion period. 1 Recent data suggest that early endocrine treatment may prolong the survival of patients with nonmetastatic disease, 17 but it is uncertain whether such treatment de®nitively inactivates a tumour. The validity of the ®nding that one-third of the tumours are nonlethal is limited by the possibility that some patients may have had a false prostate cancer diagnosis. In the present study the diagnosis was based on a histological investigation in more than 90% of the patients.
In the present series, after an early increase, the annual risk of dying of prostate cancer decreased with follow-up and almost ceased after 25 y. A similar temporal trend of the disease-speci®c risk of dying has been seen in patients with breast cancer, although with events during twice as long a period, 18 as well as in patients with prostate cancer surviving 10 y or more. 19, 20 Depending on which point on such a nonconstant hazard curve the observation of a series begins, the outcome will vary considerably and this must be taken into consideration when the assessment of the ef®cacy of treatments is based on comparisons of uncontrolled data. 21 Our ®ndings contradict those of Aus et al 22 in that the yearly risk of dying of prostate cancer in this populationbased series does not increase, but rather decreases, with follow-up time. Aus et al 22 found in their study that the yearly probability of dying of prostate cancer increases with observation time. Based on this, they argue that all patients need immediate aggressive local therapy. 23 Their study design has been severely criticised, however, 24, 25 and simulations with both this and conventional study design have shown that they probably overestimated the mortality from prostate cancer with a long follow-up. 16, 26 A previously unrecognized bias in the study design of the Gothenburg series results from the fact that the follow-up time becomes directly related to the year when the patients were diagnosed. There is an association between year of diagnosis and survival, which is re¯ected in an increased relative survival of prostate cancer over time. 27 ± 29 The`follow-up time' in the Gothenburg series 22 is related to the proportion of patients dying of prostate cancer and their`cohort' is what Miettinen 30 calls a`biased base' in that it has built in a spurious association between the outcome of interest, the proportion who died of prostate cancer, and the independent variable, ie the length of the follow-up.
The generalizability of our data to today's situation is limited by the introduction of prostate speci®c antigen (PSA). The vast majority of the patients in the present study were diagnosed before PSA came into use for detecting prostate cancer. A lead-time, perhaps in the vicinity of 5 y, has probably been introduced today by the use of PSA. 31 ± 33 In addition, the test together with improved diagnostic measures and an increased awareness may have increased the number of indolent cases detected today. However, our ®ndings suggest that even before the era of intensi®ed case ®nding and screening for prostate cancer, a subset of patients with a diagnosis of prostate cancer had non-lethal tumours with benign behaviour.
Our ®nding that somewhat less than one-third of the tumours seem to be nonlethal up to 30 y after the diagnosis substantiates the ®ndings in other large populationbased series of Helgesen et al 27 of a relative survival of 29% at 20 y follow-up and by Gro È nberg et al 16 of a relative and disease-speci®c survival at 15 y of 30%. These series included patients with all grades and stages of their prostate cancer, but because of the short median survival of patients with metastatic prostate cancer 13, 14 the patients who could be observed for 10 y or more in those series are likely to correspond to those with initially localized disease in our series.
The disease-speci®c survival rates for patients with localized disease are generally lower in the present series than in previously reported cohorts of selected patients managed by deferred treatment. 7,8,34 ± 36 One explanation certainly is that, contrary to these series, the present cohort included patients with high-grade tumours who have a worse prognosis than patients with low-grade tumours when managed with deferred treatment. 34 It is also likely that some of the patients in our series had tumours that were not locally con®ned to the prostate gland.
In the present series, the disease-speci®c survival rate was higher in more recent cohorts. Previously, an increase in relative survival over calendar time has been documented, 27, 28 corresponding to our ®ndings.
In a substantial proportion of the patients in our study, the stage of the tumours was recorded as unknown. These patients had marginally lower disease-speci®c survival rates than those registered as having localized tumours. If all patients with an unknown stage actually had localized tumours and should have been included in the group with localized tumours in the analysis, the disease-speci®c survival rates of this group would have been somewhat, but not substantially, lower. The risk of dying of prostate cancer would have also been somewhat higher, but the pattern over time would have been the same. It is not possible for us to reassess the stage of the disease in the patients in whom it was registered as unknown.
We could not assess quality of life in this series. Such data are, however, evolving concerning the complications of external radiation therapy and radical prostatectomy, 37 ± 40 especially the effects of sexual dysfunction on the quality of life. 11,12,41 ± 44 Future results from ongoing controlled trials will indicate the magnitude of unwanted and wanted effects of immediate aggressive treatment of localized prostate cancer.
So, if all patients with clinically localized prostate cancer are given radical treatment at diagnosis, it can be argued on the basis of the present data that, on average, half of the patients are over-treated with respect to survival because they will die of intercurrent disease before the tumour becomes fatal. For the remaining half, about one-third of the patients, if managed noncuratively, seem to have nonlethal tumour. Also, it is reasonable to assume that local therapy would not change the course in the majority of the patients who die early of their prostate cancer. In the present series, 28% of the patients with localized disease died of prostate cancer during the ®rst 10 y of follow-up. If no patient with localized prostate cancer is treated initially, a large proportion of the patients dying of prostate cancer after 10 y of follow-up, in this series 5% of all patients with localized tumours, are probably curable with local therapy. If these patients could be identi®ed at diagnosis, treatment with curative intent could be directed to patients with a large survival bene®t.
Our ®gures are all modi®ed by the age of the patients and they are averages for the Finnish population at the appropriate time.
